Federal University of Health Science of Porto Alegre   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Porto Alegre Brazil (1953)

Organization Overview

First Clinical Trial
2003
NCT00560079
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Alessandro Pasqualotto | Cardiology Post Graduated Program, Federal University of Rio Grande do Sul, Hospital de Clinicas de Porto Alegre | Centro Municipal de DST/AIDS, Irmandade Santa Casa de Misericordia de Porto Alegre | Complexo Hospitalar Santa Casa de Misericordia de Porto alegre | Federal Health Science University of Porto Alegre | Federal University of Health Science of Porto Alegre | Federal University of Health Sciences of Porto Alegre | Federal University of Healthy Sciences of Porto Alegre (UFCSPA) | Fundação Médica do Rio Grande do Sul | HCPA | HCPorto Alegre | Hospital das Clínicas de Porto Alegre | Hospital de Clinicas de Porto Alegre | Hospital de clínicas de porto alegre | Hospital de Clínicas de Porto Alegre | Hospital de Clinicas de Porto Algre | Hospital Espirita de Porto Alegre | Hospital of Clinics of Porto Alegre | Irmandade Santa Casa de Misericórdia de Porto Alegre | Kidney & Pancreas Transplant Unit, Santa Casa de Misericordia, Porto Alegre, Brazil | Mariane Bagatin Bermudez | Professor of the Post Graduate Program in Endocrinology at the Hospital de Clinicas de Porto Alegre | Santa Casa de Misericórdia de Porto Alegre | UFRGS and Hospital de Clínicas de Porto Alegre (HCPA)

Active Ingredients

Drugs in Phase 4 Trials (18)

allopurinol (zyloprim) (1 trial)

azithromycin (zithromax) (1 trial)

caffeine (1 trial)

cyclosporine (sandimmune) (1 trial)

diclofenac (voltaren) (1 trial)

dipyridamole (persantine) (1 trial)

everolimus (zortress) (1 trial)

hydroxychloroquine (plaquenil) (1 trial)

indacaterol (arcapta neohaler) (1 trial)

mycophenolate (CellCept) (1 trial)

scopolamine (transderm scop) (1 trial)

sirolimus (rapamune) (1 trial)

sodium chloride (1 trial)

tacrolimus (prograf) (2 trials)

thioglycolic acid (1 trial)

tiotropium (spiriva) (1 trial)

topiramate (topamax) (1 trial)

tranexamic acid (cyklokapron) (2 trials)

Drugs in Phase 3 Trials (21)

amiloride (midamor) (1 trial)

amphotericin b (fungizone) (2 trials)

bone marrow derived mesenchymal stem cells (1 trial)

borage (1 trial)

cannabidiol (Epidiolex) (1 trial)

chlorpheniramine (ChlorTrimeton) (1 trial)

chlorthalidone (Hygroton) (1 trial)

cimicifuga (1 trial)

COVID-19 convalescent plasma (1 trial)

cyproheptadine (periactin) (1 trial)

estradiol (progynon depot) (3 trials)

hydrochlorothiazide (esidrix) (1 trial)

hypericin (sgx301) (1 trial)

hypericum perforatum (1 trial)

imiquimod (aldara) (1 trial)

ketamine (ketalar) (1 trial)

liraglutide (victoza) (1 trial)

meropenem (merrem) (1 trial)

naltrexone (revia) (1 trial)

panthenol (1 trial)

testosterone (delatestryl) (1 trial)

Drugs in Phase 2 Trials (5)

acetaminophen (tylenol) (1 trial)

acetylcysteine (mucomyst) (1 trial)

autologous natural killer cells (1 trial)

losartan (cozaar) (1 trial)

melatonin (2 trials)

Drugs in Phase 1 Trials (4)

allogeneic mesenchymal stem cells (1 trial)

allogeneic natural killer cells (1 trial)

domperidone (1 trial)

tenofovir (viread) (1 trial)

Drugs in Other Trials (22)

corifollitropin alfa (1 trial)

corn (1 trial)

fluoxetine (prozac) (1 trial)

human fibrin (Tisseel) (1 trial)

icosapent ethyl (vascepa) (1 trial)

itraconazole (sporanox) (1 trial)

krill oil (1 trial)

lactobacillus delbrueckii (1 trial)

levothyroxine (Synthroid) (1 trial)

maltodextrin (1 trial)

Menotropin (Menopur) (1 trial)

phytosterol (1 trial)

progesterone (progestasert) (1 trial)

resistant starch (1 trial)

sofosbuvir (sovaldi) (1 trial)

tetracycline (tetrex) (1 trial)

triamcinolone (kenalog) (1 trial)

velpatasvir (Epclusa) (1 trial)

vitamin d3 (1 trial)

vitis vinifera (1 trial)

water (3 trials)

whey protein (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Kidney Injury (Phase 2)

Acute Pain (Phase 3)

Atherosclerosis (Phase 4)

Bipolar Disorder (Phase 4)

Brain Death (Phase 3)

Bronchopulmonary Dysplasia (Phase 4)

Cardiovascular Diseases (Phase 4)

Cheilitis (Phase 3)

Chronic Pain (Phase 3)

Common Cold (Phase 3)

Coronary Artery Disease (Phase 4)

Death (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Disease (Phase 3)

Essential Hypertension (Phase 3)

Fibromyalgia (Phase 3)

Hemorrhage (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Histoplasmosis (Phase 2)

HIV Infections (Phase 1)

Homocystinuria (Phase 2)

Hyperandrogenism (Phase 4)

Hypertension (Phase 3)

Leukemia (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Lung Diseases, Obstructive (Phase 4)

Mood Disorders (Phase 3)

Mucopolysaccharidoses (Phase 2)

Mucopolysaccharidosis IV (Phase 2)

Mucopolysaccharidosis VI (Phase 2)

Myofascial Pain Syndromes (Phase 3)

Obesity (Phase 4)

Osteochondrodysplasias (Phase 2)

Polycystic Ovary Syndrome (Phase 4)

Premenstrual Syndrome (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Schizophrenia (Phase 3)

Sleep Disorders, Circadian Rhythm (Phase 2)

Sleep Wake Disorders (Phase 2)

Syndrome (Phase 4)

Viremia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 60
  • # of Trial APIs: 70